quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· January 27, 2026

Crypto Allocations by Financial Advisors Hit All-Time High in 2025

View original at finance.yahoo.com
Crypto Allocations by Financial Advisors Hit All-Time High in 2025 Broadcast Retirement Network's Jeffrey Snyder discusses the shifting cryptocurrency landscape with Bitwise Asset Management's Matthew Hougan…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • If I had to sum up 2025 in one word, it would be mainstream

    80% confidence
  • Regulatory uncertainty was the number one blocker preventing advisors from entering crypto market for the last eight years

    80% confidence
  • Crypto has been one of the fastest growing industries in the world over the last decade and is accelerating in the new regulatory environment

    80% confidence
  • Passage of the Clarity Act would be very good for the crypto market

    80% confidence
  • The outlook is very bright for crypto in 2026

    80% confidence
  • 2025 is the year that crypto really started to go mainstream

    80% confidence
  • Crypto has become a normal and increasingly important part of global financial infrastructure

    80% confidence
  • Largest financial professionals are increasingly treating crypto as just another asset class alongside stocks, bonds and commodities

    80% confidence
  • 99 percent of advisors who owned crypto in 2024 plan to either maintain or add to their exposure in 2026

    80% confidence
  • Bitcoin is about as volatile as large cap AI stocks like Nvidia

    80% confidence
  • The crypto industry has evolved to become more institutional, regulated, and safe

    80% confidence
  • 30 to 40 percent of financial advisors are now using crypto in client accounts

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com